Citadel Advisors
KURA icon

Citadel Advisors’s Kura Oncology KURA Stock Holding History

Citadel Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$358K Sell
44,000
-43,300
-50% -$372K ﹤0.01% 10072
2025
Q4 		$907K Buy
87,300
+35,200
+68% +$369K ﹤0.01% 7611
2025
Q3 		$461K Buy
52,100
+9,300
+22% +$66.3K ﹤0.01% 9337
2025
Q2 		$247K Sell
42,800
-21,700
-34% -$133K ﹤0.01% 10242
2025
Q1 		$426K Buy
64,500
+27,600
+75% +$215K ﹤0.01% 8835
2024
Q4 		$321K Buy
36,900
+36,100
+4,513% +$519K ﹤0.01% 9515
2024
Q3 		$15.6K Sell
800
-14,100
-95% -$286K ﹤0.01% 12958
2024
Q2 		$307K Sell
14,900
-25,300
-63% -$520K ﹤0.01% 9093
2024
Q1 		$857K Buy
40,200
+33,300
+483% +$647K ﹤0.01% 7251
2023
Q4 		$99.2K Buy
6,900
+2,900
+73% +$28.5K ﹤0.01% 10945
2023
Q3 		$36.5K Sell
4,000
-12,000
-75% -$122K ﹤0.01% 12109
2023
Q2 		$169K Buy
16,000
+14,500
+967% +$171K ﹤0.01% 10138
2023
Q1 		$18.3K Sell
1,500
-18,400
-92% -$230K ﹤0.01% 13127
2022
Q4 		$247K Sell
19,900
-17,100
-46% -$249K ﹤0.01% 9718
2022
Q3 		$505K Buy
+37,000
New +$571K ﹤0.01% 8429
2022
Q1 		– Sell
-51,000
Closed -$714K – 14137
2021
Q4 		$714K Buy
+51,000
New +$826K ﹤0.01% 8784
2021
Q3 		– Sell
-11,900
Closed -$248K – 14269
2021
Q2 		$248K Buy
11,900
+4,200
+55% +$104K ﹤0.01% 11707
2021
Q1 		$218K Sell
7,700
-16,600
-68% -$525K ﹤0.01% 11529
2020
Q4 		$794K Buy
24,300
+7,000
+40% +$246K ﹤0.01% 7272
2020
Q3 		$530K Buy
17,300
+800
+5% +$17.7K ﹤0.01% 7194
2020
Q2 		$269K Buy
16,500
+4,500
+38% +$64.9K ﹤0.01% 8082
2020
Q1 		$119K Buy
12,000
+700
+6% +$8.01K ﹤0.01% 8502
2019
Q4 		$155K Buy
+11,300
New +$167K ﹤0.01% 8340

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's KURA Position: Q1 2026 in Review

Citadel Advisors reduced its Kura Oncology (KURA) stake by 5.6% in Q1 2026, selling an estimated $188K and leaving 368,825 shares worth $3M. The position accounts for ﹤0.01% of the portfolio, ranked #5268.

Citadel Advisors first reported a position in KURA in Q2 2018 and has held it in 31 quarters since. The position peaked at $100M in Q4 2020. 220 funds tracked by Wall St. Rank hold KURA as of Q1 2026.

  • Citadel Advisors held 368,825 shares of Kura Oncology worth $3M as of Q1 2026.
  • Citadel Advisors sold 21,847 Kura Oncology shares in Q1 2026, an estimated $188K.
  • Kura Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5268 holding.
  • Citadel Advisors first reported a position in Kura Oncology in Q2 2018 and has held it in 31 quarters since.
  • Citadel Advisors's Kura Oncology position peaked at $100M in Q4 2020.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.